“Snurf” Abuse Reports Revive Interest In DXM Bills
This article was originally published in The Tan Sheet
Executive Summary
A recent report of young people suspected of abusing "Snurf" has reignited interest on Capitol Hill in restricting bulk purchases of raw dextromethorphan and an age restriction on OTCs containing the cough suppressant
You may also be interested in...
FDA Risk Panel DXM Meeting Raises Stakes on Age Restriction Movement
A Drug Safety and Risk Management Advisory Committee meeting scheduled for Sept. 14 on the potential for abuse of the cough suppressant dextromethorphan could bring the OTC industry's next regulatory nightmare
FDA Risk Panel DXM Meeting Raises Stakes on Age Restriction Movement
A Drug Safety and Risk Management Advisory Committee meeting scheduled for Sept. 14 on the potential for abuse of the cough suppressant dextromethorphan could bring the OTC industry's next regulatory nightmare
FDA Risk Panel DXM Meeting Raises Stakes on Age Restriction Movement
A Drug Safety and Risk Management Advisory Committee meeting scheduled for Sept. 14 on the potential for abuse of the cough suppressant dextromethorphan could bring the OTC industry's next regulatory nightmare